ARCT
Price
$21.09
Change
+$0.82 (+4.05%)
Updated
Sep 24, 11:44 AM (EDT)
Capitalization
550.15M
42 days until earnings call
PBYI
Price
$4.56
Change
-$0.15 (-3.18%)
Updated
Sep 24, 12:20 PM (EDT)
Capitalization
237.25M
36 days until earnings call
Interact to see
Advertisement

ARCT vs PBYI

Header iconARCT vs PBYI Comparison
Open Charts ARCT vs PBYIBanner chart's image
Arcturus Therapeutics Holdings
Price$21.09
Change+$0.82 (+4.05%)
Volume$213
Capitalization550.15M
Puma Biotechnology
Price$4.56
Change-$0.15 (-3.18%)
Volume$403
Capitalization237.25M
ARCT vs PBYI Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. PBYI commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Buy and PBYI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (ARCT: $20.26 vs. PBYI: $4.71)
Brand notoriety: ARCT and PBYI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 124% vs. PBYI: 87%
Market capitalization -- ARCT: $550.15M vs. PBYI: $237.25M
ARCT [@Biotechnology] is valued at $550.15M. PBYI’s [@Biotechnology] market capitalization is $237.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whilePBYI’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • PBYI’s FA Score: 1 green, 4 red.
According to our system of comparison, PBYI is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while PBYI’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 4 bearish.
  • PBYI’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ARCT and PBYI are a good buy in the short-term.

Price Growth

ARCT (@Biotechnology) experienced а +12.00% price change this week, while PBYI (@Biotechnology) price change was +4.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.34%. For the same industry, the average monthly price growth was +10.13%, and the average quarterly price growth was +53.93%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2025.

PBYI is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+4.34% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($550M) has a higher market cap than PBYI($237M). PBYI YTD gains are higher at: 54.426 vs. ARCT (19.387). PBYI has higher annual earnings (EBITDA): 63.3M vs. ARCT (-54.54M). ARCT has more cash in the bank: 196M vs. PBYI (96M). ARCT has less debt than PBYI: ARCT (27M) vs PBYI (49.2M). PBYI has higher revenues than ARCT: PBYI (238M) vs ARCT (110M).
ARCTPBYIARCT / PBYI
Capitalization550M237M232%
EBITDA-54.54M63.3M-86%
Gain YTD19.38754.42636%
P/E RatioN/A4.76-
Revenue110M238M46%
Total Cash196M96M204%
Total Debt27M49.2M55%
FUNDAMENTALS RATINGS
ARCT vs PBYI: Fundamental Ratings
ARCT
PBYI
OUTLOOK RATING
1..100
1365
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9617
PRICE GROWTH RATING
1..100
3943
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (35) in the Biotechnology industry is in the same range as ARCT (44) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew similarly to ARCT’s over the last 12 months.

PBYI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew similarly to ARCT’s over the last 12 months.

PBYI's SMR Rating (17) in the Biotechnology industry is significantly better than the same rating for ARCT (96) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew significantly faster than ARCT’s over the last 12 months.

ARCT's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as PBYI (43) in the Biotechnology industry. This means that ARCT’s stock grew similarly to PBYI’s over the last 12 months.

PBYI's P/E Growth Rating (97) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew similarly to ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTPBYI
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
74%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 1 day ago
86%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PMDAX19.64N/A
N/A
Principal Small-MidCap Dividend Inc A
ANPRX29.92-0.02
-0.07%
Virtus NFJ Mid-Cap Value R6
LHCCX18.72-0.02
-0.11%
Lord Abbett Health Care C
ISCTX20.17-0.03
-0.15%
Voya SmallCap Opportunities Port S2
HCACX26.67-0.16
-0.60%
Hartford Capital Appreciation C

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with CLDX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-3.66%
CLDX - ARCT
51%
Loosely correlated
-2.53%
RGNX - ARCT
49%
Loosely correlated
-1.43%
MRNA - ARCT
46%
Loosely correlated
-2.90%
MGNX - ARCT
45%
Loosely correlated
-4.05%
RXRX - ARCT
45%
Loosely correlated
-3.41%
More

PBYI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with ARWR. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
+5.61%
ARWR - PBYI
35%
Loosely correlated
+1.40%
ARCT - PBYI
33%
Loosely correlated
-3.66%
DSGN - PBYI
32%
Poorly correlated
-5.20%
VRCA - PBYI
31%
Poorly correlated
-3.36%
RCKT - PBYI
30%
Poorly correlated
-2.52%
More